ABSTRACT
Objective To investigate the clinical effect of preoperative XELOX chemotherapy combined with psychological intervention on patients with advanced gastric cancer.Methods The control group, advanced gastric cancer patients underwent surgical treatment, XELOX chemotherapy was given before the operation.The study group was treated with psychological intervention on the basis of the treatment of the control group.The clinical efficacy and adverse reactions of two patients with advanced gastric cancer were recorded.Results Study group five years survival rate(63.83%),disease-free survival(42.55%),no advanced end point event probability(46.81%)was significantly higher than the control group(five and 44.68%year survival rate, disease-free survival rate was 23.40%,no advanced end point event probability 27.66%),data comparison study group P<0.05;wound healing reaction indigestion, gastrointestinal reaction, infection, oral mucositis incidence was significantly lower than the control group(P<0.05).Conclusion In the preoperative XELOX chemotherapy combined with surgical treatment on the basis of advanced gastric cancer with the corresponding psychological intervention can effectively improve the curative effect and prognosis,has positive significance to guarantee the quality of life of patients, life safety.
ABSTRACT
Objective To observe the efifcacy and safety of XELOX plus bevacizumab as a ifrst-ine treatment for Chinese patients with metastatic colorectal cancer. Methods In this study, we retrospectively reviewed cases in which XELOX plus bevacizumab were administered in order to evaluate its efifcacy and safety in clinical practice.In total, 40 patients with mCRC who presented at Fuchu Hospital received XELOX plus bevacizumab as a ifrst?line treatment from September, 2009 to April, 2012. Eligible patients had histologically conifrmed mCRC. XELOX consisted of a 2-h intravenous infusion of oxaliplatin 130 mg/m 2 on day 1 plus oral capecitabine 1,000 mg/m 2 twice daily for two weeks of athree?week cycle. Overall survival (OS) and survival benefit were analyzed when patients continued with XELOX plus bevacizumab beyond disease progression. Results The median progression?free survival (PFS) was 290 days [95%conif-dence interval (CI):222?409 days] and the median OS was 816 days (95%CI:490?842 days). The response rate (RR:complete plus partial response) was 67.5%, and the disease control rate (RR plus stable disease) was 90%. Conclusion XELOX plus bevacizumab may be considered a routine ifrst?line treatment option for patients with mCRC.